Redcare Pharmacy NV

Redcare Pharmacy NV’s 25% revenue surge hit a new all‑time low – see why the stock fell and how investors can navigate the e‑pharmacy’s future.

Redcare Pharmacy NV has reported a 25% increase in Q3 revenue to €719 million, driven by growth in the e-prescription market in Germany, solidifying its position as Europe’s largest online pharmacy by revenue.

Redcare Pharmacy NV reported a 25.2% increase in revenue to €719 million in Q3 2025, driven by the expansion of electronic prescriptions in Germany and a 27% year-over-year rise in sales, surpassing analyst expectations.

Redcare Pharmacy NV’s stock price has surged over 5% after a German court ruling and technological advancements boosted investor confidence in the online pharmacy.

Redcare Pharmacy NV’s stock plummeted 20% after analyst downgrades and concerns over its e-prescription strategy, sparking market turbulence and uncertainty about the company’s future performance.

Redcare Pharmacy NV is focusing on revenue growth despite ongoing losses, with analysts projecting a 28.04% revenue increase in its upcoming quarterly results.